Memsorb for Anesthesia Management
(memsorb Trial)
Recruiting in Palo Alto (17 mi)
Overseen byOrlando Hung, MD
Age: Any Age
Sex: Any
Travel: May Be Covered
Time Reimbursement: Varies
Trial Phase: Academic
Recruiting
Sponsor: DMF Medical Incorporated
Disqualifiers: Pregnancy, Emergency surgery, Respiratory disease, others
No Placebo Group
Trial Summary
What is the purpose of this trial?The drawbacks of chemical CO2 absorbers include the production of compounds harmful to patients that also lead into increased cost and environmental impact, as well as the daily disposal of compound special waste. Sustainable management of general anesthesia is a growing concern. Continually diluting anesthetic circuits, and the disposal of chemical granulate are serious environmental problems.
Will I have to stop taking my current medications?
The trial information does not specify whether you need to stop taking your current medications. It's best to discuss this with the trial coordinators or your doctor.
What data supports the effectiveness of the drug memsorb for anesthesia management?
The research suggests that adding dexmedetomidine to pain management can reduce the need for other pain medications like meperidine, which may imply that memsorb, if it includes similar components, could be effective in managing anesthesia by potentially reducing the amount of other drugs needed.
12345How is the drug memsorb different from other anesthesia management drugs?
Memsorb, also known as mesna, is unique because it acts as a protective agent against oxidative stress and tissue damage, which is not a common feature of typical anesthesia management drugs. It is known for its ability to neutralize harmful substances and protect tissues, which may offer additional benefits during anesthesia.
678910Eligibility Criteria
This trial is for English-speaking patients with a low to medium risk status (Class I, II, III) according to the American Society of Anesthesiologists. It's not suitable for pregnant individuals, high-risk patients (Class IV), those needing emergency surgery, or people with elevated brain pressure or severe respiratory diseases like COPD and asthma.Inclusion Criteria
American Society of Anesthesiologists Physical Status Class I, II, III (low-medium risk patient)
I speak English.
Exclusion Criteria
Self-reported as pregnant
American Society of Anesthesiologists Physical Status Class IV (high risk patient)
I am scheduled for an emergency surgery.
+2 more
Trial Timeline
Screening
Participants are screened for eligibility to participate in the trial
1-2 weeks
Treatment
Participants receive standard care using either the memsorb CO2 filter or a standard CO2 absorber during surgery
Up to 12 hours
1 visit (in-person)
Follow-up
Participants are monitored for safety and effectiveness after treatment, including measurements of various physiological parameters
1-2 weeks
Participant Groups
The study is testing 'memsorb', an innovative method aimed at removing CO2 from anesthetic circuits without using chemical granulate. This could potentially reduce harmful compounds, costs, environmental impact and the need for daily disposal of special waste.
2Treatment groups
Experimental Treatment
Active Control
Group I: memsorbExperimental Treatment1 Intervention
Patients agree to receive standard care but using memsorb, the new CO2 filter evaluated in this study.
Group II: ControlActive Control1 Intervention
Patients receive standard care with a standard CO2 absorber and agree to include their data in the study.
Find a Clinic Near You
Research Locations NearbySelect from list below to view details:
Queen Elizabeth II HSC, Halifax Infirmary SiteHalifax, Canada
Loading ...
Who Is Running the Clinical Trial?
DMF Medical IncorporatedLead Sponsor
References
Immunosuppressive Effect of Intrathecal Morphine, Dexmedetomidine, or Both in Combination with Bupivacaine on Patients Undergoing Major Abdominal Cancer Surgery. [2022]An impaired immune system in the perioperative period has important clinical implications in patients with cancer. Despite the immunosuppressive properties of opioid therapy, it is still commonly utilized in the intrathecal or epidural space for the treatment of postoperative pain. Also, intrathecal dexmedetomidine has extended analgesic efficacy in postoperative pain; it can significantly affect immune function in perioperative patients.
Anesthesia Information Management Systems: An Underutilized Tool for Outcomes Research. [2018]Perioperative outcomes research using anesthesia information management systems (AIMS) is an emerging research method that has not been comprehensively reviewed. This review reports an initial analysis of the use of AIMS for perioperative patient outcomes research from articles published between January 1980 and January 2013. Perioperative patient outcomes research based on AIMS has increased greatly since 2001. Although risk stratification studies involving large study populations were most commonly reported, AIMS were also used to report a rare life-threatening anesthesia-related complication, malignant hyperthermia. Use of AIMS for perioperative outcomes research can address clinically relevant topics that traditional research methods have been unable to adequately address, mainly because of the innate challenges presented by perioperative anesthesia practice. It is expected that perioperative effectiveness and outcomes research using large AIMS databases will be more widely embraced in the future to generate useful evidence and knowledge to improve anesthesia care.
Comparison of meperidine alone with meperidine plus dexmedetomidine for postoperative patient-controlled analgesia. [2010]To investigate if the addition of dexmedetomidine to meperidine in a patient-controlled analgesia (PCA) device would reduce postoperative meperidine consumption when compared with meperidine alone.
[Anesthesia management may alter long-term outcome-review of recent reports]. [2018]Perioperative management including anesthesia may alter long-term outcome of surgical patients. We have reviewed abstracts for meeting and articles published recently concerning effects of anesthetic depth, volatile anesthetic preconditioning, beta-blockers, alpha-agonists, statins, and glucose control on long-term outcome. Although research in this area has just been started, we, anesthesiologists should recognize its importance.
Outcomes in perioperative medicine and anesthesiology. Into the next millennium. [2019]Although the development of outcomes research in perioperative medicine and anesthesiology has focused on traditional clinical outcomes, there seems to be a transition toward more global assessments of patient-related outcomes. Present trends in outcomes research and EBM may promise an improvement in individual patient and overall quality of care. New roles and opportunities in perioperative medicine and anesthesiology provide additional venues for outcomes research in this millennium.
Prophylaxis with mesna prevents oxidative stress induced by ischemia reperfusion in the intestine via inhibition of nuclear factor-kappaB activation. [2018]Mesna (2-mercaptoethane-sulfonate) has been shown to attenuate oxidative injury induced by ischemia reperfusion (I/R) in the kidneys, the liver, and the intestine; however, its mechanism of action has not been fully elucidated. We sought to determine a prophylactic administration schedule of mesna that would confer optimal antioxidant protection on the intestinal mucosa following I/R and to investigate whether mesna's action is mediated via inhibition of nuclear factor-kappaB (NF-kappaB) activity.
Review of Advances in Uroprotective Agents for Cyclophosphamide- and Ifosfamide-induced Hemorrhagic Cystitis. [2022]Cyclophosphamide and ifosfamide are widely used drugs for malignancies and rheumatologic conditions. One of the most significant adverse reactions to these drugs is hemorrhagic cystitis. Mesna is the most widely used uroprotective agent that acts to neutralize the caustic metabolite, acrolein, responsible for induction of hemorrhagic cystitis. However, mesna is not a perfect alternative, and studies since its discovery have investigated the use of alternative drugs and adjuncts to increase mesna's efficacy. This review details some of the recent work into novel uroprotective agents for drug-induced hemorrhagic cystitis.
The Effects of MESNA on the Facial Nerve, an Experimental Animal Study. [2020]MESNA (Sodium-2-mercaptoethanesulfonate) is a mucolytic substance that is used for chemically assisted tissue dissection in various surgical operations. The aim of this study was to address the issue of possible neurotoxicity from topical administration of MESNA solution on the facial nerve. We used different concentrations of MESNA solution and evaluated their effects on facial nerve by histopathological and functional analysis.
The effects of sodium-2-mercaptoethanesulfonate application on the neural and neurovascular tissues: An experimental animal study. [2020]Sodium-2-mercaptoethanesulfonate (MESNA) is a protective agent that is also used as "a chemical dissector" in various surgical fields. The aim of this study is to evaluate the toxic effects of MESNA on neural and neurovascular structures based on a morphological analysis and examine its safety in neurotological applications.
Studies on the urotoxicity of oxazaphosphorine cytostatics and its prevention--III. Profile of action of sodium 2-mercaptoethane sulfonate (mesna). [2019]Mesna is a pharmacologically unremarkable, physiologically largely inert and almost totally non-toxic thio compound. It is rapidly eliminated renally and only slightly permeates into tissues. It has been shown experimentally that the bladder damage inducible in the rat by administration of oxazaphosphorine cytostatics can be successfully prevented by quite small doses of mesna. The detoxifying action of mesna is limited to the kidneys and the efferent urinary tract. The systemic effects of the oxazaphosphorines, however, remain unaffected. This applies particularly to the curative oncocidal efficacy of these compounds. It has also been shown experimentally that mesna does not affect the curative effects of other cytostatic drugs (doxorubicin, BCNU, methotrexate, vincristine). The efficacy of the cardiac glycoside proscillaridin is also not impaired by mesna.